Janssen Vaccines & Prevention B.V.
Clinical trials sponsored by Janssen Vaccines & Prevention B.V., explained in plain language.
Develops vaccines and preventive therapies, part of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Major RSV vaccine trial aims to protect seniors from severe lung infections
Vaccine CompletedThis large phase 3 study tested an experimental RSV vaccine in over 25,000 adults aged 60 and older. The goal was to see if a single shot could prevent lower respiratory tract disease caused by RSV, a common virus that can be dangerous for seniors. Participants received either th…
Phase 3 • Sponsor: Janssen Vaccines & Prevention B.V. • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
Universal flu vaccine takes first step in human trial
Vaccine CompletedThis study tested a new universal flu vaccine (INFLUENZA G1 mHA) in 170 healthy adults aged 18-45. The goal was to check if it is safe and triggers an immune response. Participants received either the vaccine with or without an adjuvant, or a placebo. Results will show if this ap…
Phase 1/2 • Sponsor: Janssen Vaccines & Prevention B.V. • Aim: Vaccine
Last updated Jun 26, 2026 14:27 UTC